Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine carePublished in Journal of Thrombosis and Thrombolysis, 2019Download paper hereShare on Twitter Facebook Google+ LinkedIn Previous Next